Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Relapsed or Refractory CLL/SLL The HiLOG Trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 May 2018
At a glance
- Drugs Lenalidomide (Primary) ; Methylprednisolone (Primary) ; Ofatumumab (Primary) ; Sargramostim
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms HiLOG
- 10 May 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 10 May 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 08 Dec 2017 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.